Screener
Beam Therapeutics BEAM Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total assets | $1,480,798 | $1,481,177 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $12,286 | $10,231 |
| Accrued expenses and other current liabilities | 39,291 | 55,267 |
| Current portion of derivative liabilities | 5,200 | 7,700 |
| Current portion of deferred revenue | 304 | 6,659 |
| Current portion of lease liability | 14,781 | 14,364 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's accounts payable?
- Beam Therapeutics (BEAM) reported accounts payable of $12.29M in Q1 2026.
- How has Beam Therapeutics's accounts payable changed year-over-year?
- Beam Therapeutics's accounts payable increased by 59.6% year-over-year, from $7.7M to $12.29M.
- What is the long-term trend for Beam Therapeutics's accounts payable?
- Over 4 years (2021 to 2025), Beam Therapeutics's accounts payable has grown at a 5.4% compound annual growth rate (CAGR), from $30.77M to $38.03M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Beam Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude